To evaluate the necessity of bone scanning in prostate cancer patients with serum PSA levels ≤ 20 ng/mL and Gleason scores ≤ 7, particularly focusing on implications for Asian populations.
Key Findings:
14.3% of patients had a positive bone scan.
Median PSA levels were significantly higher in patients with bone metastasis (49.6 ng/mL) compared to those without (7.3 ng/mL).
Among patients with PSA ≤ 20 ng/mL and GS ≤ 7, 25.3% had positive bone scans.
Interpretation:
The study suggests that while many patients with low PSA and GS may not require bone scans, a notable percentage still have bone metastasis, indicating that guidelines may need to be reconsidered for Asian populations based on these findings.
Limitations:
Retrospective design may introduce bias.
Findings may not be generalizable to all Asian populations due to regional differences in prostate cancer epidemiology, which should be further explored.
Conclusion:
Bone scans may still be relevant for a subset of patients with PSA ≤ 20 ng/mL and GS ≤ 7, particularly in Asian populations, despite existing guidelines suggesting otherwise, highlighting the need for a review of current practices.
With its combination of UWF imaging, OCT integration, and intelligent review tools, the MonacoPro represents the next step in comprehensive retinal evaluation. By improving image quality, enhancing diagnostic confidence, and streamlining workflow, the system supports clinicians in delivering more efficient, informed, and patient-centered care.
